Citation

Bizjak ED, Nolan PE, Brody EA, Galloway JM. Ann. Pharmacother. 1999; 33(9): 948-951.

Affiliation

College of Pharmacy, The University of Arizona, Tucson 85721, USA.

Copyright

(Copyright © 1999, Harvey Whitney Books)

DOI

unavailable

PMID

10492498

Abstract

OBJECTIVE: To describe a case of procainamide-induced psychosis in an adult treated for atrial fibrillation. CASE SUMMARY: A 45-year-old Native American woman developed acute psychosis within 72 hours of initiating procainamide for atrial fibrillation. Symptoms abated within 24 hours of discontinuing procainamide. Serum procainamide/N-acetylprocainamide concentrations were therapeutic throughout treatment. Sotalol was started without recurrence of symptoms. DISCUSSION: Psychosis is a rare complication of treatment with procainamide, but the exact mechanism for this adverse event is not fully understood. Seven cases implicating procainamide as the cause of acute psychosis are reported in the literature. Cases of psychosis involving other antiarrhythmic agents have also been reported. CONCLUSIONS: Healthcare personnel should be aware of this adverse event related to procainamide and other antiarrhythmic agents.

Language: en